[Development of thrombopoietin receptor agonists].
Miyakawa
Yoshitaka
Y
D000818:Animals; D001565:Benzoates / Q000009:adverse effects / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D055808:Drug Discovery; D006801:Humans; D006834:Hydrazines / Q000009:adverse effects / Q000627:therapeutic use; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000188:drug therapy*; D011720:Pyrazoles / Q000009:adverse effects / Q000627:therapeutic use; D011961:Receptors, Fc / Q000627:therapeutic use; D053628:Receptors, Thrombopoietin / Q000819:agonists* / Q000502:physiology; D011993:Recombinant Fusion Proteins / Q000009:adverse effects / Q000627:therapeutic use; D015398:Signal Transduction / Q000502:physiology; D013921:Thrombocytopenia / Q000188:drug therapy*; D013926:Thrombopoietin / Q000009:adverse effects / Q000627:therapeutic use
D001565:Benzoates; D006834:Hydrazines; D011720:Pyrazoles; D011961:Receptors, Fc; D053628:Receptors, Thrombopoietin; D011993:Recombinant Fusion Proteins; D013926:Thrombopoietin; C488777:romiplostim; C520809:eltrombopag